These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38647650)

  • 1. Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus.
    Denicolò S; Reinstadler V; Keller F; Thöni S; Eder S; Heerspink HJL; Rosivall L; Wiecek A; Mark PB; Perco P; Leierer J; Kronbichler A; Oberacher H; Mayer G
    Diabetologia; 2024 Jul; 67(7):1283-1294. PubMed ID: 38647650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes.
    Patel P; Gupta P; Burns A; Suwaidan AA; Cole R; Lane D; Seidu S; Khunti K
    Diabetes Care; 2019 Jun; 42(6):1132-1135. PubMed ID: 30885952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Persistent Medication Adherence and Compliance with Lifestyle Recommendations on Major Cardiovascular Events and One-Year Mortality in Patients with Type 2 Diabetes and Advanced Stages of Atherosclerosis: Results From a Prospective Cohort Study.
    Shalaeva EV; Bano A; Kasimov U; Janabaev B; Laimer M; Saner H
    Glob Heart; 2023; 18(1):61. PubMed ID: 37928361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Medication Stability in Urine for Non-Adherence Screening by LC-MS-MS.
    Burns AD; Lane D; Cole R; Patel P; Gupta P
    J Anal Toxicol; 2019 May; 43(4):325-329. PubMed ID: 30517637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study.
    Sheppard JP; Albasri A; Gupta P; Patel P; Khunti K; Martin U; McManus RJ; Hobbs FDR
    J Hum Hypertens; 2022 Dec; 36(12):1106-1112. PubMed ID: 34876657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.
    Tomaszewski M; White C; Patel P; Masca N; Damani R; Hepworth J; Samani NJ; Gupta P; Madira W; Stanley A; Williams B
    Heart; 2014 Jun; 100(11):855-61. PubMed ID: 24694797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: A narrative review.
    Denicolò S; Perco P; Thöni S; Mayer G
    J Diabetes Complications; 2021 Jul; 35(7):107931. PubMed ID: 33965338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
    Karlsson SA; Hero C; Svensson AM; Franzén S; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Eliasson B; Andersson Sundell K
    BMJ Open; 2018 Mar; 8(3):e020309. PubMed ID: 29602853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
    Ye X; Qian C; Liu J; St Peter WL
    Pharmacotherapy; 2013 Oct; 33(10):1062-70. PubMed ID: 23798059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice.
    van Bruggen R; Gorter K; Stolk RP; Zuithoff P; Klungel OH; Rutten GE
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):983-91. PubMed ID: 19623570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a medication-adherence tool: study protocol for a randomized controlled trial.
    Hilbink M; Lacroix J; Bremer-van der Heiden L; van Halteren A; Teichert M; van Lieshout J
    Trials; 2016 Jun; 17(1):274. PubMed ID: 27255080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.